Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Community-Based Screening Program to Identify, Using Blood-Based Biomarkers, Individuals With or Without Alzheimer's Disease Symptoms Who Are at High Risk for Brain Amyloid Pathology

NCT06043700 is registered in ClinicalTrials.gov with Eisai Limited as lead sponsor.

NCT NCT06043700
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06043700 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Community-Based Screening Program to Identify, Using Blood-Based Biomarkers, Individuals With or Without Alzheimer's Disease Symptoms Who Are at High Risk for Brain Amyloid Pathology
Lead sponsor
Eisai Limited
Phase
Observational
Overall status
Active, not recruiting
Start date
September 12, 2023
Completion date
March 31, 2028
Enrollment
2,000 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease